Head-to-head evidence
Eslicarbazepine acetate vs Rufinamide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Eslicarbazepine acetate · Aptiom
Marketed by Sumitomo Pharma and partners
NCT00957684 · Phase 3 · completed
The main study was randomized, quadruple-blind, placebo-controlled, and included 402 participants, with seizure frequency as a clinical primary endpoint. Although seizure frequency was lower in all eslicarbazepine groups than with placebo, the posted registry data do not state whether the prespecified primary comparison was statistically significant, so the result remains unclear.
Rufinamide
Marketed by Eisai and partners
NCT00334958 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 356 participants, and its primary clinical endpoint was change in partial-seizure frequency. The reported median change favored rufinamide (-23.25% versus -9.80% with placebo), but the registry does not state whether this primary comparison was statistically significant, so the result remains unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eslicarbazepine acetate's landscape · Rufinamide's landscape